Catalyst Event
ABL Bio Inc (298380) · Other
From KRX Bio Technology Transfer Index (KBIOTT)
6/4/2026, 12:00:00 AM
ABL Bio submitted an amended Investigational New Drug (IND) application to Korea's MFDS for its immuno-oncology candidate ABL503 on 2026-06-04. The amendment expands the ongoing Phase 1 trial to include a new monotherapy cohort and a new combination therapy arm with a PD-1 inhibitor.
Korean Translation
2026년 6월 4일, 이중항체 면역항암제 'ABL503'에 대한 임상 1상 시험계획(IND) 변경 신청서를 식품의약품안전처에 제출함. 이번 변경은 새로운 단독요법 코호트 추가 및 PD-1 억제제와의 병용요법 파트 신설을 포함함.
Related Recent Events
LigaChem Biosciences Inc (141080) · Other
Announced that partner company SOTIO Biotech received Orphan Drug Designation (ODD) from the U.S. FDA for SOT106, an ADC for osteosarcoma treatment that utilizes LigaChem's 'ConjuAll' platform technology. This validation of the platform is estimated to have a medium market impact, expected.
6/4/2026, 12:00:00 AM
Chong Kun Dang Pharm Co (185750) · Other
The company's natural new drug for gastritis, 'Zitec', is scheduled to receive conditional reimbursement approval from the Health Insurance Review and Assessment Service's (HIRA) drug evaluation committee on June 4, 2026, provided the company accepts a price below the evaluated amount. Estimated price impact >=5% as this is a critical step for market entry scheduled.
6/4/2026, 12:00:00 AM
Peptron Inc (087010) · Other
Eli Lilly exercised an option to expand its collaboration with competitor Camurus for a long-acting drug delivery technology on June 1, 2026, increasing competition for Peptron's SmartDepot platform; estimated >10% price impact expected.
6/2/2026, 12:00:00 AM
Daewoong Pharmaceutical Co Ltd (069620) · Other
Announced a partnership with Chime Biologics for the development and commercialization of a biosimilar for the immunology drug 'Dupixent', a blockbuster drug with estimated global sales of KRW 27 trillion.
6/2/2026, 12:00:00 AM
Hanmi Pharm Co Ltd (128940) · Other
Hanmi Pharm announced a licensing and collaboration agreement with Eli Lilly for its GLP-2 agonist 'Sonefpeglutide' for up to $1.26 billion on June 1, 2026, including a $75 million upfront payment.
6/1/2026, 12:00:00 AM
Voronoi Inc (310210) · Other
Voronoi presented positive clinical trial data for VRN11 at ASCO 2026 on June 1, 2026. High importance is estimated due to strong anti-tumor response in brain metastases, a major unmet need, scheduled.
6/1/2026, 12:00:00 AM